Arcellx(US:ACLX)2025-05-08 20:34Financial Position - As of March 31, 2025, Arcellx had cash, cash equivalents, and marketable securities totaling $565.2 million, expected to fund operations into 2028[7]. - Total assets as of March 31, 2025, were $648.1 million, down from $711.3 million as of December 31, 2024[14]. - Total liabilities decreased to $231.2 million as of March 31, 2025, from $256.5 million as of December 31, 2024[14]. Revenue and Expenses - Collaboration revenue decreased to $8.1 million for Q1 2025 from $39.3 million in Q1 2024, a decline of $31.2 million[8]. - Research and development expenses increased to $50.8 million in Q1 2025, up from $32.3 million in Q1 2024, an increase of $18.5 million[9]. - General and administrative expenses rose to $26.2 million in Q1 2025, compared to $22.7 million in Q1 2024, an increase of $3.5 million[10]. - Net loss for Q1 2025 was $62.3 million, compared to a net loss of $7.2 million in Q1 2024[11]. Clinical Studies - The iMMagine-3 study has added minimal residual disease negativity as a dual primary endpoint alongside progression-free survival[2]. - The iMMagine-1 data will be presented at the European Hematology Association Congress on June 14, 2025[3]. Governance - Two new Board members, Andrew Galligan and Kristin Myers, were appointed to enhance commercial and operational expertise[4][6].